Open AccessHyperammonemic encephalopathy in a patient receiving fluorouracil/oxaliplatin chemotherapy
Author(s) -
Ihoriya Hiromi,
Yamamoto Hirotsugu,
Yamada Taihei,
Tsukahara Kohei,
Inoue Kanae,
Yumoto Tetsuya,
Naito Hiromichi,
Nakao Atsunori
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1422
Subject(s) - medicine , oxaliplatin , hyperammonemia , adverse effect , encephalopathy , fluorouracil , chemotherapy , intensive care medicine , pediatrics , colorectal cancer , cancer
Key Clinical Message Hyperammonemia is a rare adverse effect of 5‐fluorouracil (5‐ FU ) therapy, but can be very serious, even fatal. Physicians must be aware that hyperammonemic encephalopathy sometimes develops as an adverse event after 5‐ FU therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom